ERC FUNDED PROJECTS

Personalized medicine is a medical model that proposes the customization of healthcare, with decisions and practices being tailored to the individual patient by use of patient-specific information and/or application of patient-specific cell-based therapies. BioBlood aims to deliver personalised healthcare through a “step change” in the clinical field of haemato-oncology. BioBlood represents an engineered bio-inspired integrated experimental/modelling platform for normal and abnormal haematopoiesis that receives disease & patient input (patient primary cells & patient/disease-specific data) and will produce cellular (red blood cell product) and drug (optimal drug treatment) therapies as its output. Blood supply to meet demand is the primary challenge for Blood Banks and requires significant resources to avoid shortages and ensure safety. An alternative, practical and cost-effective solution to conventional donated blood is essential to reduce patient morbidity and mortality, stabilise and guarantee the donor supply, limit multiple donor exposures, reduce risk of infection of known or as yet unidentified pathogens, and ensure a robust and safe turn-around for blood supply management. BioBlood aims to meet this challenge by developing a novel in vitro platform for the mass production of RBCs for clinical use. More than £32b/year is spent to develop and bring new drugs to market, which takes 14 years. Most patients diagnosed with leukaemias are unable to tolerate treatment and would benefit from novel agents. There is a need to optimise current treatment schedules for cancers such as AML to limit toxicities and improve clinical trial pathways for new drugs to enable personalised healthcare. BioBlood’s in vitro & in silico platform would be a powerful tool to tailor treatments in a patient- and leukaemia-specific chemotherapy schedule by considering the level of toxicity to the specific individual and treatment efficiency for the specific leukaemia a priori.

2 498 903 €

Start date: 2014-01-01, End date: 2018-12-31

GeopolyConc will provide the necessary scientific basis for the prediction of the long-term durability performance of alkali-activated ‘geopolymer’ concretes. These materials can be synthesised from industrial by-products and widely-available natural resources, and provide the opportunity for a highly significant reduction in the environmental footprint of the global construction materials industry, as it expands to meet the infrastructure needs of 21st century society. Experimental and modelling approaches will be coupled to provide major advances in the state of the art in the science and engineering of geopolymer concretes. The key scientific focus areas will be: (a) the development of the first ever rigorous mathematical description of the factors influencing the transport properties of alkali-activated concretes, and (b) ground-breaking work in understanding and controlling the factors which lead to the onset of corrosion of steel reinforcing embedded in alkali-activated concretes. This project will generate confidence in geopolymer concrete durability, which is essential to the application of these materials in reducing EU and global CO2 emissions. The GeopolyConc project will also be integrated with leading multinational collaborative test programmes coordinated through a RILEM Technical Committee (TC DTA) which is chaired by the PI, providing a route to direct international utilisation of the project outcomes.

1 495 458 €

Start date: 2013-09-01, End date: 2018-08-31

"Over the past years, carbon nanomaterial such as graphene and carbon nanotubes (CNTs) have attracted the interest of scientists, because some of their properties are unlike any other engineering material. Individual graphene sheets and CNTs have shown a Youngs Modulus of 1 TPa and a tensile strength of 100 GPa, hereby exceeding steel at only a fraction of its weight. Further, they offer high currents carrying capacities of 10^9 A/cm², and thermal conductivities up to 3500 W/mK, exceeding diamond. Importantly, these off-the-chart properties are only valid for high quality individualized nanotubes or sheets. However, most engineering applications require the assembly of tens to millions of these nanoparticles into one device. Unfortunately, the mechanical and electronic figures of merit of such assembled materials typically drop by at least an order of magnitude in comparison to the constituent nanoparticles. In this ERC project, we aim at the development of new techniques to create structured assemblies of carbon nanoparticles. Herein we emphasize the importance of controlling hierarchical arrangement at different length scales in order to engineer the properties of the final device. The project will follow a methodical approach, bringing together different fields of expertise ranging from macro- and microscale manufacturing, to nanoscale material synthesis and mesoscale chemical surface modification. For instance, we will pursue combined top-down microfabrication and bottom-up self-assembly, accompanied with surface modification through hydrothermal processing. This research will impact scientific understanding of how nanotubes and nanosheets interact, and will create new hierarchical assembly techniques for nanomaterials. Further, this ERC project pursues applications with high societal impact, including energy storage and water filtration. Finally, HIENA will tie relations with EU’s rich CNT industry to disseminate its technologic achievements."

1 496 379 €

Start date: 2014-01-01, End date: 2018-12-31

Most joints start off the same during embryonic development, as two opposing cartilage surfaces, and are moulded into the diverse range of shapes seen in the adult in a process known as morphogenesis. While we understand very little of the biological or mechanobiological processes driving joint morphogenesis, there is evidence to suggest that fetal movements play a critical role in joint shape development. Developmental Dysplasia of the Hip (DDH), where the hip is partly or fully dislocated, is much more common when the baby’s movement is restricted or prevented. This proposal will determine how mechanical forces influence joint shape morphogenesis, which is of key relevance to neonatal joint conditions such as DDH, to adult joint health and disease, and to tissue engineering of cartilage. A mouse line in which mutant embryos have no skeletal muscle will be studied, providing the first in depth analysis of mammalian joint shape development for normal and abnormal mechanical environments. The mouse line could provide the first mammalian model system for prenatal onset DDH. ‘Passive’ movements of these mutant embryos will then be induced by massage of the mother, and the effects on the joints measured. If the effects on joint shape of absent spontaneous movement are mitigated by the treatment, this technique could eventually be used as a preventative treatment for DDH. Next, an in vitro approach will be used to quantify how much movement is needed for joint shape development. This research will provide an optimised protocol for applying biophysical stimuli to promote cartilage growth and morphogenesis in culture, providing valuable cues to cartilage tissue engineers. Finally, a computational simulation of joint shape morphogenesis will be created, which will integrate the new understanding gained from the experimental research in order to predict how different joints shapes develop in normal and abnormal mechanical environments.

1 499 501 €

Start date: 2014-01-01, End date: 2018-12-31